Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

Experimental drug shows promise for advanced MS, delaying disability. Learn how Black Americans may benefit & why clinical trials are key.

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...